+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Keratoconus Drug"

Keratoconus - Pipeline Insight, 2024 - Product Thumbnail Image

Keratoconus - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
Progressive Keratoconus - Pipeline Insight, 2024 - Product Thumbnail Image

Progressive Keratoconus - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
Keratoconus - Epidemiology Forecast to 2032 - Product Thumbnail Image

Keratoconus - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Progressive Keratoconus - Epidemiology Forecast - 2032 - Product Thumbnail Image

Progressive Keratoconus - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Keratoconus is an optical disorder that affects the cornea, causing it to become thin and cone-shaped. This can lead to blurred vision, light sensitivity, and other vision problems. To treat this condition, drugs are used to reduce inflammation, strengthen the cornea, and improve vision. These drugs are known as Keratoconus Drugs. Keratoconus Drugs are typically administered as eye drops, tablets, or injections. They can be used to reduce inflammation, improve vision, and slow the progression of the disease. Commonly used drugs include corticosteroids, anti-inflammatory drugs, and collagen cross-linking agents. Keratoconus Drugs are used in the treatment of a variety of optical disorders, including myopia, astigmatism, and presbyopia. They are also used to treat dry eye syndrome, glaucoma, and cataracts. The Keratoconus Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Allergan, Bausch + Lomb, Novartis, Santen, and Shire. Show Less Read more